ERBB2 and breast carcinoma: As tamoxifen and trastuzumab were shown to exhibit a synergistic effect in inhibiting the growth of BT474 cells [59], we further examined the effect of AMPC inhibition of TFF3 in modulating response towards the combination of trastuzumab and tamoxifen in HER2+/ER+ breast cancer cells.